Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jason, It may not be a bad play. You know there are many women who follow Suzanne Somers and the Hollywood stars love all this type of stuff since they have so much moolah and want to preserve themselves.
Suzanne Somers Appears on CNBC's 'Conversations with Michael Eisner' and Discusses NeoStem's Adult Stem Cell Collection Program
4:00 p.m. 01/22/2009 Provided by
NeoStem Receives Substantial Number of Inquiries for its Stem Cell Collection Service
NEW YORK, Jan. 22 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NBS) announced that on January 19, 2009, Suzanne Somers appeared on "Conversations with Michael Eisner," a CNBC program that offers insightful interviews covering business, politics and entertainment topics. On the program, Ms. Somers, a NeoStem (NBS) spokesperson and successful actress, author, businesswoman and medical advocate, talked about NeoStem (NBS) and the increasing importance of adult stem cell collection and long term storage, as well as the many facets of her career. Ms. Somers, a NeoStem (NBS) client, is very open about discussing her recent stem cell collection and the importance of banking your own stem cells and is a supporter of adult stem cell research and the potential of using one's own stem cells as part of a conventional therapy to treat disease and reverse tissue damage.
Since Suzanne Somers' appearance on CNBC, NeoStem (NBS) has experienced a marked increase in inquiries from individuals citing Ms. Somers' interview as motivating them to seek out the Company's adult stem cell collection and long term storage services. Dr. Robin Smith, Chairman and CEO of NeoStem (NBS) commented, "Suzanne has been a tremendous supporter of NeoStem (NBS) and has been pivotal in launching our adult stem cell public awareness program. It is very rewarding to see the awareness of our services increasing among the general public and we attribute much of this to Suzanne's strong support of the importance of collecting and storing your own adult stem cells. NeoStem (NBS) is pleased to be able to make these services affordable through its financing program using CareCredit (a GE Money Company) that allows clients to participate in a "No Interest Payment Plan." This allows for the client to make interest free monthly payments over an 18-month period. The monthly fees, which include the collection, processing, cryopreservation and two years of storage, can be as low as $495/month. Other plans are available to extend the months of payment and lower the monthly fees.
About NeoStem, Inc. (NBS)
NeoStem (NBS) is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.
About Suzanne Somers:
Suzanne Somers has been engaged by NeoStem (NBS) to help create a multi-year awareness program to help educate the public on the increasing importance of adult stem cell collection and long term storage. This adult stem cell public awareness program was launched in September of 2008. The timing of the campaign was designed to coincide with the establishment of new stem cell collection centers in certain major metropolitan areas. In each of Ms. Somers' 17 books to date, she focuses on healthy living. "Technology may keep us alive, but without quality of life we are not living," said Ms. Somers. She has become a supporter of adult stem cell research and the potential of using one's own stem cells as part of a conventional therapy to treat disease and reverse tissue damage. Ms. Somers had her own stem cells collected in August 2008 at one of the adult stem cell collection centers in the NeoStem (NBS) network so that they are available to her for her use in the future as physician confidence in adult stem cell therapy grows. In addition to distributing the filming of Ms. Somer's own adult stem cell collection, NeoStem (NBS) may feature her in print, TV and online promotions as well as have her speak at various events. A Company of which Ms. Somers is a principal has received a warrant to purchase 600,000 shares of the Company's Common Stock in connection with her role as Company spokesperson.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the uncertainty of whether interest in and awareness of the Company's adult stem cell collection and storage services will continue, the uncertainty of whether adult stem cell therapy will ever become widely accepted as a standard therapeutic treatment, the uncertainty of whether the Company's operations will ever generate significant revenues and those set forth under "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.
Contact:
NeoStem, Inc. (NBS)
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com
www.neostem.com
SOURCE NeoStem, Inc. (NBS)
Chart: ATHX Thanks for confirming my thoughts.
Howard1231. Thank you for the bringing the stem cells to our attention.
Chart RE: ATHX. I guess the decision is do we sell without a loss since .81 is the entry and the market sucks or do we hold for a nice gain?
TW: RE: STEM and GERN
Not a bad crap shoot. When OBAMA signs the bill, they both will explode.
ATHX now at .84.
Quill,Thanks. I have AVR not ATR. AVR is a WU holding.
Just bought a little GERN. It's moving up very quickly. The FDA approval is very big since it may well be the first company to receive approval in the stem cell arena.
Good Morning Everyone. Chart-is it too late to buy the put on DRYS?
NYY, I hope I did not speak to soon.
Chart: ATHX seems to have moved up today. Not that I'm complaining. Any reason for the positive move? I haven't been able to find any news.
Thanks Quill.
STEM: Sure is booming. I decided to take a nibble at 2.16.
STEM is a good fundamental play based on the Obama. I will be buying some this afternoon based on fundamentals.
With regards to the hospital IT systems, I am not sure how much of an impact that will have on reducing premiums for healthcare. Most hospitals already have systems in place for retrieving patient information and sending it. These systems are very costly to purchase and to service.
The only thing I see as a result, is that hospitals will now wait for the money to be supplied before ugrading or expanding where as, they would need to budget it from year to year in hopes of approvals. Unless I am missing something.
FAS is moving very nicely. Thank God! Average in at 13.40 and sweating.
Okay. Good entry.
Joined you in UYG.
Super Weeeeeeeeeee!
How Kewl! Welcome QuillandPenn
Tina, I am sorry to hear about your husbands accident. I will keep him in my prayers.
Good Morning Everyone.
Sheff, I would like to add one more to your list, if you don't mind. I think I may have mentioned it a couple of months ago on WU and the company is currently partnered with KV Pharmaceuticals.
I know alot about certain companies because I am in the job market and from talking to recruiters involved with the Biotech industry. Diagnostics used in Pathology is my specialty.
Hologics (HOLX)
I have not looked at their chart recently but they are most certainly worthy of radar.
They missed earnings last quarter (and got squashed to smitterens) Once they receive FDA approval for their HPV testing BOOM! HOLX is also partnered with KV Pharmaceuticals for Gestiva most likely they have a test developed as a companion to be a requirement of the FDA approval. Approval is due 1/25/2009. They report earnings on 2/2/2009.
HOLX has spent huge money on R&D and purchases of smaller companies. They purchased Thirdwave Technologies for their HPV molecular testing. There is only one other test for HPV with FDA approval and that's owned by Quigen. Think about this, some Gyncecologists request HPV testing for all their patients Thin Preps (PAPs). They also bought are the market leader in automated thin prep testing. Their whole business is Women's Health.
I think this could be a swing trade on the approval and earnings but I also think this is a longer term play.
http://hologic.com/ah/index.cfm
I took a 2K starter position in GTCB at .60. I'm betting on the FDA approval. Looks very promising. If it goes lower, I'm buying more.
Jason, I'm in FED. Looks good.
Thanks.
Just got in GTCB for .60.
How the heck to you buy KV.A? I don't understand how to buy class A shares.
Sheff-GTCB are you thinking about buying some to hold for the approval. I know there is not guarantee but I have this feeling they will get it.
Agree with you Chart on CYCC. Stocks are down terribly and few stocks are showing any isolation. I think the optimism of Obama saving the world will show it's head next week one way or the other.
FAS. Try to get in early. Also UYG is good.
Good Morning Everyone.
Boy do I need spell check sometimes. Meant trade.
Chart-Great Treade on GSIG. I was able to join you in that one with my shares at .75. Thanks. Great postive moves on such a negative day. Patience and take the money and run is the name of the game. Bought some FAS today at 15.50.
In for 7K INVC at .135.
Go GISG.
Good Morning.
Sheff. Thanks for JSDA it took a lot of patience but patience pays off. In for 5K at .33 and watched it go up and down for about a month.
News. You would think this would move FRE.
Fed says to buy agency debt on Jan. 13Font size: A | A | A11:31 AM ET 1/12/09 | Reuters
RELATED QUOTES
11:36 AM ET 1/12/09
Symbol Last % Chg
FRE 0.74 -2.63%
FNM 0.72 -2.55%
Real time quote.
NEW YORK, Jan 12 (Reuters) - The Federal Reserve will buy debt of Fannie Mae, Freddie Mac and the Federal Home Loan Banks on Tuesday, the New York Fed said on its website on Monday.
The operation will open at 10:30 a.m. and close at 11 a.m., the New York Fed said, and will target debt maturing between January 2013 and November 2017.
The Fed will buy the securities outright in coupon purchases.
(Reporting by Kristina Cooke, Editing by Chizu Nomiyama)
Added 2K today for a total of 12K.
I have been holding 5K share of JSDA for a month now. Being very patient!